Cardiovascular Toxicity and Sorafenib

Authors:
  • LCLucía Cortejoso
    Lucía Cortejoso
  • MNMaría Tenorio Núñez
    María Tenorio Núñez
  • AMAna Matilla-Peña
    Ana Matilla-Peña
  • MSMagdalena Salcedo-Plaza
    Magdalena Salcedo-Plaza
  • MSMaría Sanjurjo-Sáez
    María Sanjurjo-Sáez
Publisher website
Google Scholar
Abstract
We report a case of a 55-year-old male with chronic hepatitis C virus infection and compensated liver disease treated with sorafenib for advanced hepatocarcinoma (Barcelona Clinic Liver Cancer stage C). At follow-up, the patient developed hypertension, which was well controlled with beta-blocker medication, and an aortic dilation detected by abdominal computerized tomography and echocardiography. There are some reports of the side effects of sorafenib on the cardiovascular system. The patient had no cardiac or aortic pathology before the start of this palliative chemotherapy. There is an article that describes the development of an aortic aneurysm in a patient with uncontrolled hypertension, who received treatment with sorafenib for renal carcinoma. However, our patient had a good control of blood pressure. The adverse vascular effects of Sorafenib may be due to the inhibition of the proliferation of vascular endothelial muscle cells. We believe that this case illustrates a probable relationship between sorafenib and aortic dilatation according to the Karch and Lasagna causality algorithm.

This publication has 9 references indexed in Scilit: